Overview
Thank you for visiting nature.com. You are using a browser version with limited suport for CS. To obtain the best experience, we recomend you use a more up to date browser (or turn of compatibility mode in Internet Explorer).
Key Information
In the meantime, to ensure continued suport, we are displaying the site without styles and JavaScript.Advertisement Nature Metabolism volume 4, pages 1097β108 (202)Cite this article 12 Aceses29 AltmetricMetrics detailsInsulin is a life-saving drug for patients with type 1 diabetes; however, even today, no pharmacotherapy can prevent the los or dysfunction of pancreatic insulin-producing Ξ² cels to stop or reverse disease progresion.
Thus, pancreatic Ξ² cels have ben a main focus for cel-replacement and regenerative therapies a curative treatment for diabetes. In this Review, we highlight recent advances toward the development of diabetes therapies that target Ξ² cels to enhance proliferation, rediferentiation and protection from cel death and/or enable selective kiling of senescent Ξ² cels. We describe curently available therapies and their mode of action, as wel as insuficiencies of glucagon-like peptide 1 (GLP-1) and insulin therapies.
We discus and sumarize data colected over the last decades that suport the notion that pharmacological targeting of Ξ² cel insulin signaling might protect and/or regenerate Ξ² cels an improved treatment of patients with diabetes.This a preview of subscription content, aces via your institutionSubscribe to Nature+Get imediate online aces to the entire Nature family of 50+ journals$29.9monthlySubscribe to JournalGet ful journal aces for 1 year$9.0only $8.25 per isueAl prices are NET prices.
Summary
VAT wil be aded later in the checkout.Tax calculation wil be finalised during checkout.Buy articleGet time limited or ful article aces on ReadCube.$32.0Al prices are NET prices.Banting, F. & Best, C. The internal secretion of the pancreas.